Milena Batalla Science Reviews - Biology, 2023, 2(2), 1 - 20

All-natural 5-MeO-DMT sigma receptor 1 agonist and

its therapeutic impact in mental and neurodegenera-

tive diseases through mitochondrial activation

Milena Batalla, PhD

Panarum Corporation, USA; milenabatalla@panarum.com

https://orcid.org/0009-0004-7002-1701

https://doi.org/10.57098/SciRevs.Biology.2.2.1

Received May 13, 2023. Revised June 20, 2023. Accepted June 22, 2023.

Abstract: The sigma-1 receptor S1R is a chaperone that resides mainly at the mitochondrion-associated

endoplasmic reticulum ER membrane MAM, it is considered a “pluripotent modulator” in living systems, plays

a critical role in maintaining neuronal homeostasis and acts as a dynamic pluripotent modulator in living

systems. Given its specific localization at the MAM, S1R plays a major role regulating mitochondrial function,

it is a therapeutic target in mental and neurodegenerative diseases including Alzheimer’s disease, Parkinson’s

disease. N,N Dimethyl Tryptamine DMT is the S1R endogen agonists and we review the role of all-natural 5-

methoxi-N,N-dimethyltryptamine 5-MeO-DMT S1R agonist that produces high levels of ego dissolution or

oceanic boundlessness higher ratings of satisfaction with life and lower ratings of depression and stress. In vitro

the 5-Meo-DMT shows strong modulation of synaptic and cellular plasticity in neurons. 5-MeO-DMT

neuropharmacological S1R agonist is implicated in cellular bioenergetics activation, antiapoptotic and

mitochondrial regulation of epigenetic landscape in neurons. S1R has been considered as a controller of cell

survival and differentiation in neurons. The pharmacological benefits of all-natural 5-MeO-DMT are currently

under research. This review compendia results, highlighting the key molecular mechanisms of S1Rs on

mitochondrial functions and epigenetic modifications involved in the health and sickness phenotype

development, and describe the possible pharmacological use of all-natural 5-MeO-DMT to “rescue” patients

from sickness phenotype through mitochondrial activation. We focus on all-natural 5-MeO-DMT its clinical

therapeutic implications benefit long-term effects on mental health and well-being of the patient possibly

reprogramming and remodeling the epigenome, particularly in mental and neurodegenerative diseases.

Keywords: Sigma1 receptor, mitochondria, energy, dysregulation, stress, ROS, epigenetic, disease, all-natural,

5MeO-DMT, therapy.

Introduction

Hundreds of millions of people worldwide are af-

fected by the pandemic of mental

and neurodegen-

erative

diseases. Given the specific localization of

the Sig-1R at the MAM, have been very explored as

target regulations of the Sig-1R in mental and to

neurodegenerative diseases including Alzheimer’s

disease (AD), Parkinson’s disease (PD), among oth-

ers

. Sig-1R ligands are fundamental on mitochon-

drial dysfunction-induced neurodegeneration are

addressed. DMT is the endogen agonist of sigma

receptor and in this report, we particularly review,

the role of all-natural 5-Meo-DMT as a pharmaco-

logical agonist for the Sigma 1 receptor

. All-natural

5-methoxy-N,N-dimethyltryptamine, hereinafter

referred to as all-natural 5-MeO-DMT, is a entheo-

gen substance found in the secretion from the paro-

toid glands of the Bufo alvarius toad is agonist of

Sigma 1 receptor. The all-natural 5-MeO-DMT ad-

ministrated in humans in naturalistic settings as a

treatment of mental health problems and as a means

for spiritual exploration is currently researched.

Numerous patents and clinical studies that describe

Milena Batalla Science Reviews - Biology, 2023, 2(2), 1 - 20

the pharmacological benefits of 5-MeO-DMT are

ongoing

The mitochondria are the power station that pro-

vides the necessary energy for the processes that

sustaining life

. The mitochondria perform diverse

interconnected functions, producing ATP and

many biosynthetic intermediates while also contrib-

uting to cellular stress responses such as autophagy,

apoptosis and epigenetic regulation

. Mitochondria

form a dynamic, interconnected network that is in-

timately integrated with other cellular compart-

ments. In addition, mitochondrial functions extend

beyond the boundaries of the cellular influence and

organism's physiology by regulating communica-

tion between cells and tissues. These characteristics

define mitochondria both as fundamental compo-

nents of our cells specially in neurons

. Mitochon-

drial dysfunction has emerged as a key factor men-

tal

and neurodegenerative disorders

. In this re-

view we focus the regulation of cellular functions

through the mitochondrial bioenergetic, signaling,

antiapoptotic and epigenetics regulation pathways.

Hence, we provide an innovative perspective in

which we highlight the key molecular mechanisms

advances in sigma-1 receptors on mitochondrial

functions and epigenetic regulation on healthiness

and sickness, with special focus on mental and neu-

rodegenerative diseases and clinical implications of

all-natural 5-MeO-DMT S1R agonist.

Mitochondria: In Healthiness and In Sickness

Mitochondria are critical to cell and organ function;

Mitochondria play a key role in metabolic homeo-

stasis, because of their central role in energy pro-

duction, control of cytosolic Ca2+ (calcium ion) lev-

els, lipid homeostasis, steroid synthesis, generation

of Fe-S (iron–sulfur) centers, heme synthesis

, in-

nate immune response, and metabolic cell signal-

ing

12–16

. For all the above mentioned, mitochondrial

dysfunction and altered organellar regulation are

also associated with some more common diseases,

including cancers, mental, neurodegenerative dis-

eases

12,13

. Mitochondria are the main regulator of

cell survival/death as well as that for the ROS pro-

duction.

Mitochondria produce ATP via oxidative phos-

phorylation (OXPHOS). In the matrix, tricarboxylic

acid cycle (TCA) enzymes generate electron carriers

(NADH and FADH2), which donate electrons to the

IM-localized electron transport chain (ETC) and

also generate reactive oxygen species (ROS) which

can damage key components of cells, including li-

pids, nucleic acids, and proteins

. ROS has been

suggested to contribute to diseases associated with

mitochondrial dysfunction, including neurodegen-

eration.

Another central function of mitochondria is ROS

signaling and sensing. Mitochondria operates as re-

dox sensors that can alter energy states in response

to the chemical environment of the cell and relative

levels of endogenous metabolites such as iron (II),

succinate, and ascorbate, as well as various forms of

ROS. However, how ROS sensing is mediated by

mitochondrial function and how different ROS

sensing pathways overlap are not well understood.

Changes in redox states influence DNA methyla-

tion because the oxidation of 5-methylcytosine to 5-

hydroxymethylcytosine in CpGs can perturb recog-

nition by methyl-binding proteins and subse-

quently alter methylation patterns and epigenetic

regulation

7,15

Metabolic epigenetics refers to nuclear alterations of

chromatin and other factors that regulate gene ex-

pression resulting from changes in mitochondrial

energetics and metabolism. The resulting metabo-

lites, in turn, mediate gene expression changes that

control cellular processes, including energy homeo-

stasis

. Thus, energy status and metabolism are

able to modulate epigenetic programming via chro-

matin structural changes and dynamics, DNA

methylation, histone modifications, and non-coding

RNA expression. Epigenetic modifiers include

DNA methyltransferases, histone acetyl transfer-

ases, histone deacetylases, sirtuins (SIRTs), histone

lysine demethylases, poly(ADP-ribose) polymer-

ases, and others that work coordinately to regulate

gene expression. For instance, reprogramming of

energy metabolism has been identified as hallmark

of cancer

and epigenetic control

18,19

Mitochondrial distribution and dynamics are influ-

enced by physical interaction between the mito-

chondrial outer membrane and diverse intracellular

membranes, such as the plasma membrane, peroxi-

somes, ER, autophagosomes and lysosomes, termed

mitochondria-associated membranes (MAMs).

MAMs create unique environments or platforms for

the localization and activity of components that

function in shared inter-organellar functions, such

as Ca2+ homeostasis and lipid biosynthesis

20-22

MAM is critical in maintaining neuronal homeosta-

sis. Thus, given the specific localization of the S1R

at the MAM, we highlight and propose that the di-

rect or indirect regulations of the S1R on mitochon-

drial dysfunctions intervenes to mental and

Science Reviews - Biology, 2023, 2(2), 1 - 20 Milena Batalla

neurodegenerative diseases

. Neurons and muscle

cells contain high levels of mitochondria due to a

high demand of energy. The Central Nervous Sys-

tem (CNS) has a high rate of metabolism because

neurons participate in facilitating the neurotrans-

mission and extending axons and dendrites to

neighboring cells for impulse transmission

. Neu-

rons exert plasticity, exhibiting complex morpholo-

gies, and constitutively undergo synaptic modula-

tions when stimulated. Therefore, mitochondrial

dysfunction detrimental to neurons and has been

extensively discussed in neurodegeneration

Biological and physiological function of Sigma

receptors in mitochondria

Biological and physiological function of Sigma re-

ceptors in mitochondria The S1R is a small (28 kDa),

highly conserved, chaperone that resides mainly at

the mitochondrion-associated endoplasmic reticu-

lum (ER) membrane (called the MAMs) and acts as

a dynamic pluripotent modulator in living sys-

tems

. Chaperones are proteins that assist the cor-

rect folding of other protein clients. The S1R is

known to play a role in regulating the Ca2+ signal-

ing between ER and mitochondria and in maintain-

ing the structural integrity of the MAM

. The MAM

serves as bridge between ER and mitochondria reg-

ulating multiple functions such as Ca2+ transfer,

energy exchange, lipid synthesis and transports,

and protein folding that are pivotal to cell survival

and defense. Therefore, the S1R serves as a commu-

nicator that bridges these two organelles and plays

pivotal roles in mitochondrial functions

Interestingly, the percentage of newly synthesized

proteins that are correctly folded and thus are able

to exit the ER is usually less than 10%. Because the

action of chaperones is fundamental to the cell,

chaperones are implicated in many diseases includ-

ing Huntington disease

, Parkinsonism

, stress

disorders

. Under pathological conditions, the S1R

is a receptor chaperone essential for the metabo-

tropic receptor signaling and for the survival

against cellular stress losing its global Ca2+ homeo-

stasis the S1R translocates and counteracts the aris-

ing apoptosis

The S1R receptor has a unique and versatile phar-

macological profile

4,32

and its endogenous agonist is

Dimethyl tryptamine (DMT). S1R ligands have

therapeutic usages in regulating the stability of IP3

receptors as well as the associated interorganelle

Ca2+ signaling from the ER to mitochondrion un-

der normal or otherwise pathological conditions

33-

. S1R bind with high affinity to several classes of

chemically unrelated ligands such as neuroster-

oids

, neuroleptics, dextrobenzomorphans [DEX]

and several psychostimulants such as cocaine

methamphetamine [METH]

37,38

methylenediox-

ymethamphetamine [MDMA]

and methacathi-

none

37,40

. Consequently, it is thought that the SR

may mediate the immunosuppressant, antipsy-

chotic

and neuroprotective effects of many drugs

S1Rs regulate a number of neurotransmitter sys-

tems, including the glutamatergic [Glu], dopamin-

ergic [DA], serotonergic [5HT], noradrenergic [NE]

and cholinergic [Ch] systems. As these transmitters,

which interact with the S1Rs, are involved in many

neuropsychiatric disorders their role has been eval-

uated in a number of these disorders

. In fact, sev-

eral lines of research have demonstrated that S1R

play a role in the pathophysiology of neuropsychi-

atric disorders such as mood

, anxiety disorders

and schizophrenia

26,46

The acute S1R actions include the modulation of ion

channels (e.g. K+ channel), N-methyl-D-aspartate

receptors (NMDARs)

, IP3R and s1R translocation.

Chronic actions of S1Rs are considered to be the re-

sult of an up- or down regulation of the S1R itself.

Recent in vitro and in vivo studies strongly point

that S1Rs participate in membrane remodeling and

cellular differentiation in the nervous system recon-

stitution in the brain implicated on drug abuse

Metabolic studies support the view that S1R have

functional significance in brain glucose metabolism

as glucose utilization is affected by ligands in areas

of brain that show high densities of sRs

. S1R might

possess a constitutive biological activity, and that

S1R ligands might merely work as modulators of

the innate activity of this protein. The lack of post-

natal development of receptors in the CNS, and the

fact that S1R sites are much denser in peripheral or-

gans, such as the liver

, immune and endocrine tis-

sues

50,51

, suggest a universal role for sRs in cellular

function. Because of their widespread modulatory

role, S1R ligands have been proposed to be useful

in several therapeutic fields such as amnesic and

cognitive deficits, depression and anxiety, schizo-

phrenia, analgesia and against some effects of drugs

of abuse such as cocaine and METH and neuro-

degenerative diseases

40,52

The mitochondrial role of the sigma1 receptor

in neurodegenerative diseases

Given the specific localization of the S1R at the

MAM, we highlight and propose that the direct or

Milena Batalla Science Reviews - Biology, 2023, 2(2), 1 - 20

indirect regulations of the S1R on mitochondrial

functions intervenes to neurodegenerative diseases.

These receptors represent compelling putative tar-

gets for pharmacologically treating neurodegenera-

tive disorders. Neurodegenerative diseases with

distinct genetic etiologies and pathological pheno-

types appear to share common mechanisms of neu-

ronal cellular dysfunction, including excitotoxicity,

calcium dysregulation, oxidative damage, ER stress

and mitochondrial dysfunction

53,54

Sustained release of glutamate causes persistent ac-

tivation of NMDARs leading to neuronal excitotox-

icity, increasing intracellular calcium levels, fol-

lowed by stochastic failure of calcium homeostasis

and necrotic cell death

. This toxicity results from

activation of the mitochondrial permeability transi-

tion pore opening triggered by membrane poten-

tial-dependent uptake of calcium into the mito-

chondrial matrix

53,54

, contributing to neurodegener-

ation in acute and chronic CNS diseases, including

ALS, AD, and PD disease

55-57

. Hence, one major

mechanism by which S1R ligands may confer neu-

roprotection is through the regulation of intracellu-

lar calcium homeostasis

The best evidence that ROS may be an underlying

cause of neurodegeneration is the strong associa-

tion between the detection of increased ROS pro-

duction and the increased oxidative damage ob-

served in CNS disorders such as PD, AD and

ALS

59,60

. Activation of Sig-1Rs may also mitigate

ROS accumulation, possibly through modulation of

ROS-neutralizing proteins. Furthermore, Sig-1R

knockout or knockdown can increase oxidative

damage

Protein aggregation occurs under calcium dysregu-

lation, oxidative stress or aging, altering ER func-

tion and leading to the accumulation of unfolded or

misfolded proteins within the ER lumen. This trig-

gers a stress response by the ER known as the un-

folded protein response (UPR) to restore protein

folding homeostasis. The failure of protein homeo-

stasis is a common mechanism for many neuro-

degenerative diseases AD, PD, and HD

62,63,64

Mitochondrial fission and fusion are part of normal

organellar maintenance, and are particularly signif-

icant in axons, in which mitochondria may have to

travel long distances. Recent work has identified

that the dynamin-related protein 1 (Drp1) is re-

cruited to ER-mitochondria contact sites and medi-

ates fission and it’s been shown that homozygous

knockout of Drp1 is lethal

, while fragmented mi-

tochondria and elevated or modified Drp1 (i.e., in-

creased fission activity) are associated with AD, PD,

and HD

. Mitochondria-MAM dysregulation has

been proposed as the underlying cause of AD

and

may contribute to neuronal loss in other disease

contexts

S1Rs may also influence the expression of anti- and

pro-apoptotic signals that target the mitochondria.

Sig-1R activity positively regulates Bcl-2 expres-

sion, possibly through nuclear factor kappa B (NF-

kB) and/or extracellular signal-regulated kinase

(ERK) pathways

68,69

. Since Bcl-2 has also been

shown to interact with IP3Rs and enhance their ac-

tivity

, this positive regulation of Bcl-2 level may be

another mechanism by which sigma 1 activity in-

creases IP3R-mediated mitochondrial calcium up-

take and ATP production, in addition to the S1R-

IP3R interaction described above. Activation of

S1Rs may also decrease expression of Bax and apop-

tosis associated caspases, further promoting cell

survival

3,70,71

Alzheimer Disease (AD) is a complex, multifactorial

disease characterized by severe cognitive impair-

ment and memory loss. Decreased S1R protein lev-

els were observed in the human living

and cortical

postmortem brain tissue

72,73

and similar results

were found in PET scan studies, in which Sig-1R ex-

pressions were lower in the brain of early AD pa-

tients

.S1R expression may be involved in the ther-

apeutic effect of HDAC6 inhibitor on AD pathol-

ogy

. Preclinical evidences suggest that S1R ago-

nists might be useful in treating AD, no selective

S1R agonist is currently available for clinical use

specific sigma 1 receptor agonist as all-natural 5-

MeO-DMT

has advantages to be consider in clini-

cal use.

Parkinson’s disease (PD) is a slowly progressing

disorder, causing impaired motor functions such as

bradykinesia or tremor, and other non-motor com-

plications. The pathological characteristic of PD is a

massive death of dopaminergic neurons in substan-

tia nigra pars compacta (SNpc) and the deposit of

Lewy bodies composed of α-synuclein, ubiquitin

and neurofilaments. S1R expressions were lower in

putamen of PD patients as demonstrated by PET

studies

. S1R also attenuate Dopamine (DA) tox-

icity involved in the etiology of PD

. S1R agonists

were found to reduce oxidative stress via several

signaling pathways

. Endogenous S1Rs could toni-

cally inhibit DA-induced NF-κB activation, which

protects cell from death. Thus, S1R ligands may rep-

resent new therapeutic targets for PD

. These data

suggest that S1Rs are one of the endogenous

Science Reviews - Biology, 2023, 2(2), 1 - 20 Milena Batalla

substrates that counteract the dopamine cytotoxi-

city that would otherwise cause apoptosis

Endogenous DMT and all-natural 5-MeO-DMT are

sigma 1 receptor agonists - Mode of action

Endogenous DMT is Sigma 1 receptor agonist a

molecule synthesized, stored, and released it is ag-

onist of S1R

in cells periphery and central nervous

system

. DMT is Central Nervous System neuro-

transmitter involved in sensory perception

. En-

zyme indolethylamine-N-methyltransferase

(INMT), is the responsible of DMT synthesis

INMT is widely expressed in the body, primarily in

peripheral tissue such as the lungs, thyroid and ad-

renal gland, skeletal muscle, heart, small intestine,

stomach, retina, pancreas, lymph nodes and

blood

. It is densely located in the anterior horn of

the spinal cord

82–87

. Highest INMT activity has been

found within the brain in the following areas: un-

cus, medulla, amygdala, frontal cortex

, frontal-pa-

rietal and temporal lobes

87,88

, pineal gland

and pla-

centa

. DMT has been measured in several human

body fluids, including blood

, urine and cerebral

spinal fluid. Endogenous DMT binds to sigma-1 re-

ceptors as an agonist at half maximal effective con-

centration EC50 = 14 μM. INMT co-localizes with

sigma 1 receptor in C-terminals of motor neurons

Only a small fraction of endogenous DMT is re-

leased into the bloodstream

. DMT has a transport

process

accomplished via ATP-dependent uptake

similar to the biological priority of glucose and

amino acids, showing the universal role DMT in bi-

ological processes. The three-step process by which

DMT is accumulated and stored in neurons are de-

scribed

. Once uptake and storage of DMT has

been completed, it has remained stored in vesicles

for at least 1 week and to be released under appro-

priate stimuli

. Through these three steps, periph-

eral synthesis of DMT, consumption of DMT con-

taining plant matter, or systemic administration of

DMT can influence central nervous system func-

tions

. In cardiovascular system the effect of DMT

was determined, by administration of DMT to hu-

man volunteers, a progressive decrease in heart rate

was observed over the four doses, but not in blood

pressure

Endogenous DMT plays a significant role in physi-

ological mechanisms via S1R-MAM-mitochondrial

pathway. S1R

agonists are neuroprotective via

several mechanisms. DMT and also 5-MeO-DMT

reduced inflammation via S1R and induced neu-

ronal plasticity

, which is a long-term regenerative

process that goes beyond neuroprotection

. DMT

and 5-MeO-DMT modulate innate and adaptive in-

flammatory responses through the S1R of human

monocyte-derived Dendritic cells

. DMT mediated

S1R activity induces neuronal plasticity changes in

newborns

. Exogeneous DMT stimulates the in

vitro differentiation of neural progenitors toward a

neuronal phenotype through S1R. DMT in vivo ac-

tion mediated by S1R improved performance in

learning tasks that has been linked to hippocampal

neurogenesis. Moreover, previous studies per-

formed in humans

, using the traditional medicine

of native peoples of South America Ayahuasca

which main component is DMT infusion

has anti-

depressant activity, a therapeutic effect usually

linked to hippocampal neurogenesis

100

All-natural 5-MeO-DMT is found as a natural ex-

tract from the secretions of the Sonoran Desert Bufo

alvarius toad gland and is considered an Amerin-

dian medicine Seris, an aboriginal group from the

state of Sonora, in Mexico

. Some reports suggest

that the secretion of the Bufo alvarius toad have been

used historically by native peoples in the south-

western territory of the USA and northern Mex-

ico

101

. This entheogenic sigma 1 receptor agonist

has recently been associated with cognitive gains,

antidepressant effects and changes in brain areas re-

lated to attention and neural regeneration

. 5-MeO-

DMT is a neuroregulatory substance, sigma-1 re-

ceptor

is its neuropharmacological target. 5-MeO-

DMT is the most potent entheogen with strong dis-

solution of the ego, a conscious state marked by a

loss or diminution of one’s sense of self and a lack

of first-person experience

102

, influence on percep-

tion

, cellular bioenergetics activation, antiapop-

totic

and mitochondrial regulation of epigenetics.

5-MeO-DMT mechanism of action is mediated S1R

signaling pathway a “pluripotent modulator” in

living systems, as a controller of cell survival and

differentiation

25,58

. The S1R is the primary pharma-

cological molecular targets for 5-MeO-DMT and its

mitochondrial activation play roles dissolving

symptoms of some psychiatric and neurodegenera-

tive disorders by the epigenetic regulate

. Possibly,

5-MeO-DMT shed light into the therapy on recov-

ery patients health from mental diseases and neuro-

degenerative diseases.

In vivo pharmacology studies of 5-MeO-DMT

have

been conducted in mice, rats, gerbils, hamsters,

guinea pigs, rabbits, goldfish, cats, dogs, sheep, pigs

and primates. The pharmacokinetics of 5-MeO-

Milena Batalla Science Reviews - Biology, 2023, 2(2), 1 - 20

DMT has been studied the maximum concentration

(Cmax) in plasma is reached after 5–6 min following

an intraperitoneal (IP) injection, the terminal half-

life (t1/2) is 12–19 min in mice and Cmax = 5–10 min

and t1/2 = 6–16 min in rats. 5-MeO-DMT presents a

hydrophobic behavior (3.3 oil/water partition coef-

ficient) and readily crosses the blood–brain barrier

(BBB). 5-MeO-DMT is distributed to the liver, kid-

neys and brain. Brain concentrations of 5-MeO-

DMT in the rat were 1.7-fold higher compared to

plasma after IP injection, with highest concentra-

tions in the cortex, thalamus, hippocampus, basal

ganglia, medulla, pons and cerebellum. In the

mouse brain, 5-MeO-DMT distributes to the cortex,

hippocampus, hypothalamus and striatum after IP

administration

4,92

. It has been demonstrated that

the pharmacokinetics of 5-MeO-DMT follows a

non-linear pattern for both IP and intravenous (IV)

administration of high doses in mice. This non-line-

arity is also reflected in corresponding increases in

brain concentration of 5-MeO-DMT. This enzyme

mediates the production of the psychoactive metab-

olite bufotenine from 5-MeO-DMT

Long-term potentiation (LTP) is a persistent

strengthening of synapsis based on recent patterns

of activity. These are patterns of synaptic activity

that produce a long-lasting increase in signal trans-

mission between two neurons

103

. The opposite of

LTP is long-term depression, which produces a

long-lasting decrease in synaptic strength. Specifi-

cally, 5-MeO-DMT modulates proteins associated

with long-term potentiation. Proteins found upreg-

ulated by 5-Meo-DMT are NMDAR, CaMK2

(Ca2+/calmodulin-dependent protein kinase), and

CREB (cyclic AMP-responsive element-binding

protein)

5-MeO-DMT is a weak 5-HT reuptake inhibitor but

has no appreciable effects on monoamine release

nor on noradrenaline or dopamine. S1R contributes

to the brain plasticity effects of 5-MeO-DMT. S1R is

an endogenous regulator of dendritic spine mor-

phology and neurite outgrowth

104,105

. 5-MeO-DMT

is a direct molecular mediator of plasticity, which

has effects on cell surface and extracellular proteins

involved in regulating synaptic architecture. An up-

regulation of integrins

, netrins, plexins, and sem-

aphorins were observed in 5-MeO-DMT-treated or-

ganoids, was also found in major depressive disor-

der patients who responded well to antidepres-

sants, suggesting the importance of this class of pro-

teins in brain plasticity. srGAP, an intracellular

signaling molecule with a role in processes under-

lying synaptic plasticity, higher cognitive function,

learning, and memory is significantly downregu-

lated

106

. S1R agonists exert neuroprotective effects

by regulating intracellular calcium levels

107

, pre-

venting expression of pro-apoptotic genes

108

, and

protecting mRNA against anti-apoptotic genes such

as Bcl-23. Psychological effects such as changes in

perception and thought, renewed sensation of nov-

elty, ineffability, and awe

109

possible is derive di-

rectly from the strong modulation of synaptic and

cellular plasticity promoted by 5-MeO-DMT.

Mitochondria-directed epigenetic changes and

role of 5-MeO-DMT

Cells respond to environmental stressors through

several key pathways, including

response to ROS, nutrient and ATP sensing, DNA

damage response, and epigenetic alterations. Mito-

chondria play a central role in these pathways

through energetics, ATP production, metabolites

generated in TCA cycle, also through and mito-

chondria–nuclear signaling related to mitochondria

morphology, biogenesis, fission/fusion, mitoph-

agy, apoptosis, and epigenetic regulation

110

Possibly the neuroprotective, neuroregeneration,

anti-apoptosis and neuroplasticity

111

effects from 5-

MeO-DMT agonist S1R is mediated through mito-

chondrial epigenetic regulation pathway. Each neu-

ron contains up to 2 million mitochondria

112

. The

energy-hungry brain is especially vulnerable to

power station problems during mitochondrial dam-

age

113

. Mitochondrial regulation of epigenetic land-

scape alterations are reversible, epigenetic pro-

cesses early in life might play a role in defining in-

ter-individual trajectories of human behavior and

epigenetic mechanisms contribute to later-onset

neurological dysfunction and disease

. Some epi-

genetics diseases targets with significant neuronal

death and neurological dysfunction include Alz-

heimer’s Disease (AD), Parkinson’s Disease (PD),

Huntington’s Disease (HD), epilepsy, stroke and

traumatic brain injury (TBI)

114

. Alterations of the

S1R gene have been associated with severe neuro-

degenerative disorders

mtDNA damage or mitochondrial damage has been

associated with a mitochondrial damage check-

point “mitocheckpoint”

115

. OXPHOS defect is

checkpoint mechanism induced due to instability of

the nuclear genome

116

. The mitocheckpoint coordi-

nates and maintains the proper balance between

apoptotic and anti-apoptotic signals. Upon damage

Science Reviews - Biology, 2023, 2(2), 1 - 20 Milena Batalla

to mitochondria, mitocheckpoint is activated to

help repair damage to mitochondria, restore normal

mitochondrial function, avoid induction of mito-

chondria-defective cells and induce changes to the

nuclear epigenome

117

. Cross talk between the nu-

cleus and mitochondria of individual cells may lead

to a mitochondrial damage response as a result of

incurred damage. If mitochondria are severely

damaged, such an event will trigger apoptosis. If

damage to mitochondria is persistent and defective

mitochondria accumulate in the cell, it would lead

to instability of the nuclear genome

114

DNA methylation is a major epigenetic modifica-

tion of DNA gene expression possible mitochondria

regulated

. Epigenetic modifications within the

mammalian nuclear genome include DNA methyl-

ation (5-mC) or hydroxymethylation (5-hmC)

118,120

Mammalian mitochondria have recently been iden-

tified to have mitochondrial DNA methyltransfer-

ase 1 (mtDNMT1) activity, 5-mC and 5-hmC. Shock

et al. identified translocation of nuclear DNMT1 to

the mitochondrial matrix is regulated by expression

of a conserved mitochondria targeting sequence,

upstream of the gene’s transcription start site

within the nuclear encoded gene

120

. Alterations in

mtDNMT1 directly affected transcription from the

light and heavy strands of mtDNA suggesting a cor-

relation between 5-hmC and 5-mC mediated tran-

scriptional regulation of mtDNA by a nuclear en-

coded gene. These findings provide new evidence

implicating epigenetic regulation of the mitochon-

drial genome by nuclear encoded translocated

mtDNMT1 relative to mitochondrial dysfunc-

tion

121–123

. Reduced levels of co-factors due to mito-

chondrial impairment/ dysfunction could have sig-

nificant effects on regulation of the nuclear genome.

Mitochondrial dysfunctions invoke mitochondria-

to-nucleus retrograde responses in human cells

124

Mitochondrially targeted DNMT1 transcript vari-

ant (mtDNMT1) comprises about 1–2% of total

DNMT1 transcripts and is upregulated by the hy-

poxia-responsive transcription factors peroxisome

proliferator-activated receptor gamma coactivator 1

alpha (PGC1a) and nuclear respiratory factor 1

(NRF1) and via the release of p53 from the DNMT1

promoter

125

. This finding suggests that mtDNMT1

plays a regulatory role during oxidative stress, con-

firming the link between oxidative stress and mito-

chondrial function. Similar capacities for

mtDNMT1 and its nuclear counterpart were indi-

cated by the finding that mtDNMT1 shows clear

CpG-dependent mtDNA interactions proportional

to the amount of CpGs in the target amplicons

126

The reduced mtDNA methylation is the result or a

consequence of this mitochondrial dysfunction.

mtDNA methylation activation would be involved

in mitochondrial biogenesis (LSP, HSP1) and

maintenance of the electron transport chain

(HSP2)

127

Maternal mitochondrial imprinting and chromo-

somes imprinting from parents’ patterns, would

represent a biological memory of what the parents

experienced

128

. Transmission caused by environ-

mental factors, such as the parents’ childrearing be-

havior

129

. That these transgenerational effects have

been also epigenetically transmitted to their chil-

dren. Integrating both hereditary and environmen-

tal factors through the lifetime, epigenetics adds a

new and more comprehensive transgenerational

transmission of trauma

130

, nightmares

131

, posttrau-

matic stress disorder PTSD

132

, symptoms in mental

diseases and the neurodegeneration. Moreover, the

transmission may continue beyond the second gen-

eration and also include the grandchildren, great

grandchildren and perhaps others as well. This pro-

cess of transgenerational transmission of trauma

(TTT) has been repeatedly described in the aca-

demic literature for more than half a century

131

. The

epigenetic marks affect gene expression patterns in

the nervous system and mitochondrial dysfunction

and epigenetic imbalance show to influence the pro-

gression of many mental and neurological disor-

ders

128

. S1R agonist

5-MeO-DMT

are possible

through epigenetic regulation by activation mito-

chondrial pathway reversible promote restoring to

healthy cellular functions by restoring the epige-

netic landscape.

Familial early-onset Alzheimer’s disease (AD) is

more probable in individuals coming from mothers

diagnosed with AD than from fathers diagnosed

with AD. Studies in animal models have shown ma-

ternal imprinting in the ovum lead to alterations ge-

netic and/or epigenetic in the nuclear and/or the

mitochondrial DNA. These modifications that are

transmitted to the new living beings affect more mi-

tochondrial proteins and, therefore, the mitochon-

drial function may be affected in adulthood by

trends present in the ovum

133

PD, AD

133

, HD and other neurodegenerative dis-

eases

123

and forms of acute brain injury

. In our per-

spective is possible activation of epigenetic

Milena Batalla Science Reviews - Biology, 2023, 2(2), 1 - 20

mechanism

through S1-R and mitochondrial func-

tion in mental and neurodegenerative diseases,

whose restore by 5-MeO-DMT agonist promote ac-

tivation mitochondrial pathways, mitochondria bi-

oenergetics function

134–137

, mitochondrial oxidative

respiration

138

and mitochondrial epigenetic regula-

tion, restored mtDNMT nuclear activity, increasing

levels mitochondrial FAD and α-KG co-factors who

have significant effects on regulation of the nuclear

genome. 5-MeO-DMT modulates proteins involved

in long-term potentiation (LTP), in addition to mor-

phogenesis and maturation of dendritic spines,

while inhibiting neurodegeneration and apoptosis.

5-MeO-DMT activate score for dendritic spine and

cellular protrusion formation, microtubule and cy-

toskeletal organization. Biological functions such as

neurodegeneration, apoptosis, and neuron lesion

are inhibited by 5-MeO-DMT

through S1R-mito-

chondria pathway.

Figure 1: 5-MeO-DMT Sigma 1 receptor agonist nuclear epigenetic regulation/chromatin modification through mito-

chondria–via sirtuins (e.g., SIRT1 and SIRT6), HDACs, and HATs, which require acetyl CoA from the TCA cycle; nu-

trient sensing through the NAD+/NADH and ATP/AMP sensing; catalysis of H3K4me2 and H3K27me3, demethyla-

tion mediated by LSD1 and the JMJD protein family, catalyzed using mitochondria synthesized co-factors FAD and α-

ketoglutarate. DNA repair and redox signaling pathways. Dialog mitochondria and nucleus: mtDNMTs are associated

with healthy mitochondria. The reduced mtDNA methylation is the result of mitochondrial dysfunction. mtDNMT1

from nucleus are translocated in mitochondrial dysfunction.

Clinical implications of the therapeutic use of

all-natural 5-MeO-DMT

All-natural 5-MeO-DMT

139

is high potency, ultra-

rapid onset, and short duration of entheogen ef-

fects, primarily is sigma 1 receptor agonist. Native

peoples of North, Central, South America, included

Amazon region America possibly used the ancestral

medicine in millenary sacred ritualist healing and

consciousness evolution purposes according their

cosmovision. All-natural 5-MeO-DMT produces

profound altered state of consciousness and ego

dissolution, including mystical experiences as inner

experiences involving an intensely felt fading of the

sense of self and/or feelings of increased connect-

edness, up to and including the sense of complete

unity

163

. These kinds of feelings go well beyond our

normal day to day sense of self-awareness. In ordi-

nary consciousness, there is generally the impres-

sion that there is a me on the one hand and then, on

the other hand, everything else. Under some cir-

cumstances, however, this sense of self ––during

such moments, one’s sense of self can fade into the

background and become a part of, rather than apart

Metabolites for

epigenetic regulation

• NAD+

• ATP

• SAM

• α-Ketoglutarate

• Acetyl CoA

5-MeO-DMT

Sigma 1 Receptor

FAD FADH2

O2 H2O2

α–KG

LSD1

JMJD

DNMTs

REDOX signaling

Nutrient

sensing

Target

Genes

Target

Genes

DNA repair

Apoptosis

Cell cycle

arrest

NAD+

NADH

H2O2

SOD

ADP+ Pi

ATP

Epigenetic

regulation

ATP/AMP

Science Reviews - Biology, 2023, 2(2), 1 - 20 Milena Batalla

from, everything else

140

, with beneficial long-term

effects on mental health and well-being of the pa-

tient

139

Naturalistic use of toad secretion containing 5-

MeO-DMT was reported that the intensity of the ex-

perience is associated with improvements in

measures of satisfaction with life and reduction of

psychological distress in participants without an

underlying mental health condition

141

. Effects fol-

lowing natural 5-MeO-DMT administration are al-

teration in auditory and time perception, emotional

states amplifications, and strong ego dissolution

short-lasting, and reliably induces a “peak” mysti-

cal spiritual experience

141

, state consider to be a core

predictor of the efficacy of entheogen all-natural 5-

MeO-DMT

139

. 5-MeO-DMT cause rapid and sus-

tained reductions in symptoms of depression, anxi-

ety, and stress. 5-MeO-DMT also stimulates neuro-

endocrine function and immunoregulation

Formulations of interest are smoked, vaped, IM, in-

tranasal, intravenous for high bioavailability of 5-

MeO-DMT because they avoid first-pass metabo-

lism. Smoked and vaporized administration pro-

vides fast onset of subjective experiences with high

intensity and short duration. At present, biophar-

maceutical companies with an interest in synthetic

5-MeO-DMT are exploring and developing vapor-

ized, intranasal, IM, and intravenous formulations

for delivering 5-MeO-DMT

141,142

. In a dose-ranging

Phase I clinical trial to assess safety and psychoac-

tive effects of 5-MeO-DMT, demonstrated the safety

of vaporized dosing up to 18 mg for administration

via inhalation. Importantly, the rapid onset and

short duration of the 5-MeO-DMT experience ren-

der it more suitable for individual dose-finding

strategies compared with longer-acting psychedel-

ics

143

Clinical implication of the all-natural 5-MeO-DMT

receptor sigma agonist and its role on mitochon-

drial activation it is possible applicated to the ther-

apy of serious psychiatric disorders—Schizophre-

nia (SCZ), major depressive disorder (MDD), and

borderline personality disorder (BPD) diseases with

a different range of debilitating symptoms and

prognosis, and show similar alterations in energy

metabolism processes

144

. Proteomic data show that

SCZ and BPD share 32 altered proteins, mostly re-

lated to mitochondrial electron transport, response

to ROS and glycolysis. They share some pathophys-

iological traits and data analysis revealed seven

proteins altered both in BPD and MDD, while five

of those are different subunits of the NADH dehy-

drogenase complex in the electron transport

chain

144

. This is consistent with previous reports of

impaired functioning of OXPHOS complexes in

MDD

144,145

and decreased nuclear expression of

genes coding for mitochondrial respiratory mecha-

nisms in BPD

146

both of which lead to reduced mi-

tochondrial energy production. major depression

has been described as the initial symptom of mito-

chondrial disease in a large sample size of adult pa-

tients

147

. Mitochondrial function and energy metab-

olism were shown to play an important role in reg-

ulating social behaviors

148

. Limited energy produc-

tion impairs adaptive neuronal capacity and con-

tribute to the development of psychopathologies

such as SCZ, BPD, and MDD under stressful stimu-

lus

149

All-natural 5-MeO-DMT patented composition

comprise its possible use in the therapy to mental

and neurodegenerative diseases

139

. One of the most

important benefit uses of all-natural 5-MeO-DMT

reported are the patient’s recovery from addiction

prompted by cocaine

. S1R mediated cocaine has

dose-dependent interaction between histone

deacetylase (HDAC)1, HDAC3 and HDAC3 and to

therefore affect chromatin compaction and gene ex-

pression

149

. All-natural 5-MeO-DMT via S1R activa-

tion trigger patients’ recovery from symptom with

persistent improvements in life satisfaction and

psychopathological symptoms

139,141,150,151,152

. A sin-

gle dose, 24-hour-treatment with 5-MeO-DMT,

showed major downregulation of mGluR5 after

treatment with 5-MeO-DMT. mGluR5 has a role in

the rewarding effects for several drugs of abuse. It

was shown that mice lacking the mGluR5 gene do

not self-administer cocaine and show no cocaine-in-

duced hyperactivity

153

. They also have attenuated

somatic signs of nicotine withdrawal, and reduced

ethanol consumption behavior

154

, suggesting

mGluR5 is involved in addiction

4,155

All-natural 5-MeO-DMT-mediated S1R is involved

in the reported retrieval and healing of traumatic

memories

139,156

: “Epigenetic modifications, such as

DNA methylation, occur in response to environ-

mental influences to alter the functional expression

of genes in an enduring and potentially, intergener-

ationally transmissible manner. As such, they may

explain interindividual variation, as well as the

long-lasting effects of trauma exposure”

132

. The

Milena Batalla Science Reviews - Biology, 2023, 2(2), 1 - 20

reconsolidation and fear extinction of traumatic

memories require the involvement of epigenetic

mechanisms. Several countries where 5-MeO-DMT

is unregulated offer retreats and treatment pro-

grams

157

. A survey of 51 US Special Operations

Forces Veterans from one such retreat, with com-

bined 5-MeO-DMT and ibogaine treatments, indi-

cated the experience was therapeutic for their trau-

matic experiences, suicidal ideation, depression and

anxiety

155,157

In a survey of 20 individuals from the

same retreat center, 75% reported a ‘complete mys-

tical experience’, as measured by MEQ-30

155,158

Notable features of natural 5-MeO-DMT are the re-

ported high rates of the ego-dissolution and mysti-

cal experiences, with long-term positive therapeutic

outcomes is calling for consistent pharmacognosy

and clinical exploration

158

. Some of the benefits re-

lated to 5-MeO-DMT mediated by S1R and mito-

chondrial function to mitigate symptoms of some

psychiatric and neurodegenerative disorders symp-

toms are linked possibly to these extensive epige-

netic modifications produced by 5-MeO-DMT-S1R-

mitochondrial epigenetic pathway. For this reason,

all-natural 5-MeO-DMT S1R ligand is of great inter-

est as possible therapeutic agent against CNS disor-

ders

24,148

Conclusion

Mental

159

and neurodegenerative

160

diseases are the

possible epigenetics regulation complex products

from under environmental or epigenetically inher-

itance stress manifested and controlled by S1R-

MAM-mitochondrial dysfunction with large degree

of variation depending on the neurons tissue af-

fected. Endogenous and exogenous DMTs are

sigma 1 receptor agonist and regulate adult neuro-

genesis in vitro and in vivo with mental health ben-

efits and antidepressant

effects in patients

98,99,100

. We

have reviewed comprehensively a possible strong-

est neurobiological reprogrammed with the novel

pharmacological sigma 1 receptor agonist the all-

natural 5-MeO-DMT

139

ancestral healing via Sig-1R-

MAM-mitochondrial activation. S1R is an ER resi-

dent chaperone that is highly enriched at the MAMs

that controls mitochondria Ca2+ flux, bioenergetic,

oxidative and stress responses and mitochondrial

epigenetic regulation. Pharmacological S1R agonist

5-MeO-DMT therapeutic implications in mental

and neurodegenerative diseases such as Alzheimer,

Parkinson will drive the most important resources

for expansion of all-natural 5-MeO-DMT successful

legal therapy.

References

1. A J Ferrari, D F Santomauro, A M M Herrera, J Shadid, C Ashbaugh, H E Erskine, F J Charlson, M

Naghavi, S I Hay, T Vos, and H A Whiteford. Global, regional, and national burden of 12 mental

disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of

Disease Study 2019. Lancet Psychiatry (2022); 9: 137–50.

https://doi.org/10.1016/S2215-0366(21)00395-3

2. William M Carroll. The global burden of neurological disorders. Lancet Neurology (2019) 18, 5,

418 – 419. https://doi.org/10.1016/S1474-4422(19)30029-8

3. Nguyen, L. et al. Role of sigma-1 receptors in neurodegenerative diseases. J. Pharmacol. Sci. (2015)

127, 17–29. https://doi.org/10.1016/j.jphs.2014.12.005

4. Dakic, V. et al. Short-term changes in the proteome of human cerebral organoids induced by 5-

MeO-DMT. Sci. Rep. (2017) 7, 12863. https://doi.org/10.1038/s41598-017-12779-5

5. Anna O Ermakova, Fiona Dunbar, James Rucker and Matthew W Johnson. A narrative synthesis

of research with 5-MeO-DMT. Journal of Psychopharmacology 2022, Vol. 36(3) 273–294.

https://doi.org/10.1177/02698811211050543

6. Jodi Nunnari and Anu Suomalainen. Mitochondria: In Sickness and in Health. Cell; (2012) 148 (6):

1145–1159. https://doi.org/10.1016/j.cell.2012.02.035

7. Minocherhomji, S., Tollefsbol, T. O. & Singh, K. K. Mitochondrial regulation of epigenetics and its

role in human diseases. Epigenetics (2012) 7, 326–334. https://doi.org/10.1016/j.cell.2012.02.035

8. Carlos Cardanho-Ramos and Vanessa Alexandra Morais. Mitochondrial Biogenesis in Neurons:

How and Where. Int J Mol Sci. (2021) 22 (23): 13059. https://doi.org/10.3390/ijms222313059

Science Reviews - Biology, 2023, 2(2), 1 - 20                                                                                                             Milena Batalla                      
11 
 
9.  Shaw-Hwa  Jou,  Nan-Yin  Chiu,  Chin-San  Liu.  Mitochondrial  Dysfunction  and  Psychiatric 
Disorders. Chang Gung Med J (2009) 32, 370-9. 
  10. Hariharan Murali Mahadevan, Arsalan Hashemiaghdam, Ghazaleh Ashrafi and Angelika Betti
  na Harbauer. Mitochondria in Neuronal Health: From Energy Metabolism to Parkinson’s Disease. 
  Adv. Biology (2021), 5, 2100663, 1 of 18. https://doi.org/10.1002/adbi.202100663 
11.  Kalainayakan, S.  P.,  FitzGerald,  K. E.,  Konduri,  P. C.,  Vidal, C.  & Zhang,  L. Essential  roles  of 
mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis. Cell Biosci. (2018) 
8, 56. https://doi.org/10.1186/s13578-018-0257-8 
  12.  Fariss,  M.  W.  Role  of  mitochondria  in  toxic  oxidative  stress.  Mol.  Interv.  (2005)  5,  94–111. 
  https://doi.org/10.1124/mi.5.2.7 
13. Van Houten, B., Woshner, V. & Santos, J. H. Role of mitochondrial DNA in toxic responses to 
oxidative stress. DNA Repair (2006) 5, 145–152. https://doi.org/10.1016/j.dnarep.2005.03.002 
  14. Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem. J. (2009) 417, 1–13. 
  https://doi.org/10.1042/BJ20081386 
15. Hitchler, M. J. & Domann, F. E. Redox regulation of the epigenetic landscape in Cancer: A role for 
metabolic reprogramming in remodeling the epigenome. Free Radic. Biol. Med. (2012) 53, 2178–2187. 
https://doi.org/10.1016/j.freeradbiomed.2012.09.028 
  16. Wallace, D. C., Fan, W. & Procaccio, V. Mitochondrial Energetics and Therapeutics. Annu. Rev. 
  Pathol. Mech. Dis. (2010) 5, 297–348. https://doi.org/10.1146/annurev.pathol.4.110807.092314  
17. Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell (2011) 144, 646–
674. https://doi.org/10.1016/j.cell.2011.02.013 
  18. Nakajima, E. C. & Van Houten, B. Metabolic symbiosis in cancer: Refocusing the Warburg lens. 
  Mol. Carcinog. (2013) 52, 329–337. https://doi.org/10.1002/mc.21863 
19. Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. (2016) 
17, 487–500. https://doi.org/10.1038/nrg.2016.59 
  20. Hayashi, T., Rizzuto, R., Hajnoczky, G. & Su, T.-P. MAM: more than just a housekeeper. Trends 
  Cell Biol. (2009) 19, 81–88. https://doi.org/10.1016/j.tcb.2008.12.002 
21.  Rizzuto,  R.  &  Pozzan,  T.  Microdomains  of  Intracellular  Ca  2+:  Molecular  Determinants  and 
Functional Consequences. Physiol. Rev. (2006) 86, 369–408.   
 https://doi.org/10.1152/physrev.00004.2005 
  22. Voelker, D. R. Genetic and Biochemical Analysis of Non-Vesicular Lipid Traffic. Annu. Rev. Bio
  chem. (2009) 78, 827–856. https://doi.org/10.1146/annurev.biochem.78.081307.112144  
23. Kelly Anne Chamberlain and Zu-Hang Sheng. Mechanisms for the maintenance and regulation 
of axonal energy supply. J Neurosci Res. (2019) 97(8): 897–913. https://doi.org/10.1002/jnr.24411 
24. Weng, T.-Y., Tsai, S.-Y. A. & Su, T.-P. Roles of sigma-1 receptors on mitochondrial functions rele
 vant to neurodegenerative diseases. J. Biomed. Sci. (2017) 24, 74. https://doi.org/10.1186s12929-017-
0380-6 
25.  Mori,  T.,  Hayashi,  T.,  Hayashi,  E.  &  Su,  T.-P.  Sigma-1  Receptor  Chaperone  at  the  ER-
Mitochondrion  Interface Mediates the  Mitochondrion-ER-Nucleus  Signaling  for  Cellular Survival. 
PLoS ONE (2013) 8, e76941. https://doi.org/10.1371/journal.pone.0076941 
  26. Rousseaux, C. G. & Greene, S. F. Sigma receptors [ σ Rs]: biology in normal and diseased states. 
  J. Recept. Signal Transduct. (2015) 1–62. https://doi.org/10.3109/10799893.2015.1015737 
27.  Hayashi, T. The  Sigma-1 Receptor in Cellular Stress Signaling.  Front. Neurosci. (2019) 13, 733. 
https://doi.org/10.3389/fnins.2019.00733 

Milena Batalla                                                                                                             Science Reviews - Biology, 2023, 2(2), 1 - 20                                                                                                                                                                          
12 
 
  28.  Carmichael,  J.  et  al.  Bacterial  and  yeast  chaperones  reduce  both  aggregate  formation  and  cell 
  death  in  mammalian  cell  models  of  Huntington’s  disease.  Proc.  Natl.  Acad.  Sci.  (2000)  97,  9701–
  9705. https://doi.org/10.1073/pnas.170280697 
29.  Kabuta,  T.  & Wada, K.  Insights  into  links between  familial and  sporadic  Parkinson’s disease: 
Physical  relationship  between  UCH-L1  variants  and  chaperone-mediated  autophagy.  Autophagy 
(2008) 4, 827–829. https://doi.org/10.4161/auto.6560 
  30. Caamaño, C. A., Morano, M. I. & Akil, H. Corticosteroid receptors: a dynamic interplay between 
  protein folding and homeostatic control. Possible implications in psychiatric disorders. Psychophar
  macol. Bull. (2001) 35, 6–23. 
31. Tsai, S.-Y., Hayashi, T., Mori, T. & Su, T.-P. Sigma-1 Receptor Chaperones and Diseases. Cent. 
Nerv. Syst. Agents Med. Chem. (2009) 9, 184–189.   
httpss://dx.doi.org/10.2174/1871524910909030184 
  32.  Hayashi, T.  The Sigma-1 Receptor in Cellular Stress Signaling.  Front. Neurosci. (2019) 13, 733. 
  https://doi.org/10.3389/fnins.2019.00733 
33. Su, T.-P., Hayashi, T., Maurice, T., Buch, S. & Ruoho, A. E. The sigma-1 receptor chaperone as an 
inter-organelle signaling modulator. Trends Pharmacol. Sci. (2010) 31, 557–566.   
https://doi.org/10.1016/j.tips.2010.08.007 
  34. Su, T.-P., Su, T.-C., Nakamura, Y. & Tsai, S.-Y. The Sigma-1 Receptor as a Pluripotent Modulator 
  in  Living  Systems.  Trends  Pharmacol.  Sci.  (2016)  37,  262–278.https://doi.org/10.1016/
  j.tips.2016.01.003 
35. Yano, H. et al. Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer 
assays. Neuropharmacology (2018) 133, 264–275.   
 https://doi.org/10.1016/j.neuropharm.2018.01.042 
  36. Mishra, A. K. et al. The sigma-1 receptors are present in monomeric and oligomeric forms in li
  ving cells in the presence and absence of ligands. Biochem. J. (2015) 466, 263–271. https://doi.org/
  10.1042/BJ20141321 
37. Bastianetto, S., Ramassamy, C., Poirier, J. & Quirion, R. Dehydroepiandrosterone (DHEA) protects 
hippocampal  cells  from  oxidative  stress-induced  damage.  Mol.  Brain  Res.  (1999)  66,  35–41. 
https://doi.org/10.1016/S0169-328X(99)00002-9 
  38. Kaushal, N. & R. Matsumoto, R. Role of Sigma Receptors in Methamphetamine-Induced Neuro
  toxicity. Curr. Neuropharmacol. (2011) 9, 54–57. https://dx.doi.org/ 10.2174/157015911795016930 
39. Kaushal, N. et al. CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic 
effects  of  methamphetamine  in  mice.  Neuropharmacology  (2011)  61,  992–1000. 
https://doi.org/10.1016/j.neuropharm.2011.06.028 
  40.  Brammer, M. K.,  Gilmore,  D. L.  & Matsumoto, R. R.  Interactions  between 3,4-methylenedioxy
  methamphetamine  and  σ1  receptors.  Eur.  J.  Pharmacol.  (2006)  553,  141–145.  https://doi.org/
  10.1016/j.ejphar.2006.09.038 
41. Meririnne, E., Kankaanpää, A., Lillsunde, P. & Seppälä, T. The Effects of Diazepam and Zolpidem 
on  Cocaine-  and  Amphetamine-Induced  Place  Preference.  Pharmacol.  Biochem.  Behav.  (1999)  62, 
159–164. https://doi.org/10.1016/S0091-3057(98)00139-7 
42. Cormaci, G., Mori, T., Hayashi, T. & Su, T.-P. Protein Kinase A Activation Down-Regulates, Whe 
 reas Extracellular Signal-Regulated Kinase Activation Up-Regulates σ-1 Receptors in B-104 Cells: I
 mplication for Neuroplasticity. J. Pharmacol. Exp. Ther. (2007) 320, 202–210.   
https://doi.org/10.1124/jpet.106.108415  

Science Reviews - Biology, 2023, 2(2), 1 - 20                                                                                                             Milena Batalla                      
13 
 
43. Cobos, E., Entrena, J., Nieto, F., Cendan, C. & Pozo, E. Pharmacology and Therapeutic Potential 
of Sigma1 Receptor Ligands. Curr. Neuropharmacol. (2008) 6, 344–366.   
https://dx.doi.org/10.2174/157015908787386113 
  44.  Paschos, K. A., Veletza,  S. &  Chatzaki, E.  Neuropeptide and  Sigma  Receptors  as Novel  Thera
  peutic  Targets  for  the  Pharmacotherapy  of  Depression:  CNS  Drugs  (2009)  23,  755–772.   
  https://doi.org/10.2165/11310830-000000000-00000 
45. Kulkarni, S. K. & Dhir, A. σ-1 receptors in major depression and anxiety. Expert Rev. Neurother. 
(2009) 9, 1021–1034. https://doi.org/10.1586/ern.09.40 
46. Su, T.-P., Hayashi, T. & Vaupel, D. B. When the Endogenous Hallucinogenic Trace Amine N,N -
 Dimethyltryptamine Meets the Sigma-1 Receptor. Sci. Signal. (2009) 2.   
https://doi.org/10.1126/scisignal.261pe12    
47. Nguyen, L., Lucke-Wold, B. P., Mookerjee, S., Kaushal, N. & Matsumoto, R. R. Sigma-1 Receptors 
and  Neurodegenerative  Diseases:  Towards  a  Hypothesis  of  Sigma-1  Receptors  as  Amplifiers  of 
Neurodegeneration  and  Neuroprotection.  in  Sigma  Receptors:  Their  Role  in  Disease  and  as 
Therapeutic Targets (eds. Smith, S. B. & Su, Springer International Publishing (2017) T.-P. Vol. 964 
133–152. https://doi.org/10.1007/978-3-319-50174-1_10 
48. Hayashi, T. & Su, T.-P. The potential role of sigma-1 receptors in lipid transport and lipid raft re
 constitution  in  the  brain:  Implication  for  drug  abuse.  Life  Sci.  (2005)  77,  1612–1624. 
https://doi.org/10.1016/j.lfs.2005.05.009        
49. Gill, S. S. & Pulido, O.  M. Review Article:  Glutamate Receptors in Peripheral Tissues: Current 
Knowledge, Future Research, and Implications for Toxicology. Toxicol. Pathol. (2001) 29, 208–223. 
https://doi.org/10.1080/019262301317052486 
  50. Wolfe, S. A., Culp, S. G. & De Souza, E. B. σ-Receptors in Endocrine Organs: Identification, Cha
  racterization,  and  Autoradiographic  Localization  in  Rat Pituitary, Adrenal, Testis, and  Ovary.  En
  docrinology (1989) 124, 1160–1172. https://doi.org/10.1210/endo-124-3-1160 
51. Wolfe, S. A., Kulsakdinun, C., Battaglia, G., Jaffe, J. H. & De Souza, E. B. Initial identification and 
characterization of sigma receptors on human peripheral blood leukocytes. J. Pharmacol. Exp. Ther. 
(1988) 247, 1114–1119. 
52. Narayanan, S., Mesangeau, C., H. Poupaert, J. & R. McCurdy, C. Sigma Receptors and Cocaine 
 Abuse. Curr. Top. Med. Chem. (2011) 11, 1128–1150.   
 https://dx.doi.org/10.2174/156802611795371323 
53.  Al-Saif,  A.,  Al-Mohanna,  F.  &  Bohlega,  S.  A  mutation  in  sigma-1  receptor  causes  juvenile 
amyotrophic lateral sclerosis. Ann. Neurol. (2011) 70, 913–919. https://doi.org/10.1002/ana.22534 
  54. Luty, A. A. et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar 
  degeneration-motor  neuron  disease.  Ann.  Neurol.  (2010)  68,  639–649.  https://doi.org/10.1002/
  ana.22274 
55. Lau, A. & Tymianski, M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflüg. Arch. 
- Eur. J. Physiol. (2010) 460, 525–542. https://doi.org/10.1007/s00424-010-0809-1 
  56.  Hazell,  A.  Excitotoxic mechanisms  in  stroke:  An  update  of concepts and treatment strategies. 
  Neurochem. Int. (2007) 50, 941–953. https://doi.org/10.1016/j.neuint.2007.04.026 
57. Mancuso, R. et al. Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS 
Mice. Neurotherapeutics (2012) 9, 814–826. https://doi.org/10.1007/s13311-012-0140-y 
58. Hayashi, T. & Su, T.-P. Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regula
 te Ca2+ Signaling and Cell Survival. Cell (2007) 131, 596–610.   
https://doi.org/10.1016/j.cell.2007.08.036 

Milena Batalla                                                                                                             Science Reviews - Biology, 2023, 2(2), 1 - 20                                                                                                                                                                          
14 
 
59. Reynolds, A., Laurie, C., Lee Mosley, R. & Gendelman, H. E. Oxidative Stress and the Pathogenesis 
of Neurodegenerative  Disorders.  in International  Review  of Neurobiology. Elsevier (2007) vol.  82 
297–325. https://doi.org/10.1016/S0074-7742(07)82016-2 
  60. Lin, M. T. & Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative di
  seases. Nature (2006) 443, 787–795. https://doi.org/10.1038/nature05292 
61.  Mori,  T.,  Hayashi, T.  & Su, T.-P.  Compromising  σ-1  Receptors  at the Endoplasmic  Reticulum 
Render Cytotoxicity to Physiologically Relevant Concentrations of Dopamine in a Nuclear Factor-
κB/Bcl-2-Dependent  Mechanism:  Potential  Relevance  to  Parkinson’s  Disease.  J.  Pharmacol.  Exp. 
Ther. (2012) 341, 663–671. https://doi.org/10.1124/jpet.111.190868 
62. Hetz, C. & Mollereau, B. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative 
diseases. Nat. Rev. Neurosci. (2014) 15, 233–249. https://doi.org/10.1038/nrn3689 
63. Pal, A. et al. The sigma-1 receptor protects against cellular oxidative stress and activates antioxi
 dant response elements. Eur. J. Pharmacol. (2012) 682, 12–20.   
https://doi.org/10.1016/j.ejphar.2012.01.030 
64. Halliday, M. & Mallucci, G. R. Targeting the unfolded protein response in neurodegeneration: A 
new approach to therapy. Neuropharmacology (2014) 76, 169–174.   
https://doi.org/10.1016/j.neuropharm.2013.08.034 
  65. Ishihara, N. et al. Mitochondrial fission factor Drp1 is essential for embryonic development and 
  synapse formation in mice. Nat. Cell Biol. (2009) 11, 958–966. https://doi.org/10.1038/ncb1907 
66.  Chaturvedi, R. K. & Flint Beal,  M. Mitochondrial  Diseases of the  Brain. Free Radic.  Biol. Med. 
(2013) 63, 1–29. https://doi.org/10.1016/j.freeradbiomed.2013.03.018 
67. Schon, E.  A. & Area-Gomez, E. Mitochondria-associated ER membranes in Alzheimer disease. 
Mol. Cell. Neurosci. (2013) 55, 26–36. https://doi.org/10.1016/j.mcn.2012.07.011 
68.  Vance,  J.  E.  MAM  (mitochondria-associated  membranes)  in  mammalian  cells:  Lipids  and 
 beyond.   Biochim.  Biophys.  Acta  BBA  -  Mol.  Cell  Biol.  Lipids  (2014)  1841,  595–609. 
https://doi.org/0.1016/j.bbalip.2013.11.014 
69.  Rizzuto,  R. et al.  Ca2+  transfer  from  the  ER  to  mitochondria:  When,  how  and  why. Biochim. 
Biophys. Acta BBA - Bioenerg. (2009) 1787, 1342–1351. https://doi.org/10.1016/j.bbabio.2009.03.015 
  70. Tchedre, K. T. & Yorio, T. σ-1 Receptors Protect RGC-5 Cells from Apoptosis by Regulating Int
  racellular  Calcium,  Bax  Levels,  and Caspase-3  Activation. Investig.  Opthalmology  Vis. Sci.  (2008) 
  49, 2577. https://doi.org/10.1167/iovs.07-1101 
71. Smiraglia, D., Kulawiec, M., Bistulfi, G. L., Ghoshal, S. & Singh, K. K. A novel role for mitochondria 
in  regulating  epigenetic  modifications  in  the  nucleus.  Cancer  Biol.  Ther.  (2008)  7,  1182–1190. 
https://doi.org/10.4161/cbt.7.8.6215 
72. Hedskog L, Pinho CM, Filadi R, Ronnback A, Hertwig L, Wiehager B, et al. Modulation of the 
endoplasmic reticulum-mitochondria interface in AD and related models. Proc Natl Acad Sci U S A. 
(2013)110:7916e7921. https://doi.org/10.1073/pnas.1300677110 
73. Jansen KL, Faull RL, Storey P, Leslie RA. Loss of sigma binding sites in the CA1 area of the anterior 
hippocampus  in  AD  correlates  with  CA1  pyramidal  cell  loss.  Brain  Res.  (1993)  623:  299e302. 
https://doi.org/10.1016/0006-8993(93)91441-T 
  74. Mishina M, Ohyama M, Ishii K, Kitamura S, Kimura Y, Oda K, et al. Low density of s1 receptors 
  in early AD. Ann Nucl Med. (2008); 22:151e156. https://doi.org/10.1007/s12149-007-0094-z 
75. Iwamoto, M., Nakamura, Y., Takemura, M., Hisaoka-Nakashima, K. & Morioka, N. TLR4-TAK1-
p38 MAPK pathway and HDAC6 regulate the expression of sigma-1 receptors in rat primary cultured 
microglia. J. Pharmacol. Sci. (2020) 144, 23–29. https://doi.org/10.1016/j.jphs.2020.06.007 

Science Reviews - Biology, 2023, 2(2), 1 - 20                                                                                                             Milena Batalla                      
15 
 
  76. Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K, et al. Function of s1 recep
  tors in PD. Acta Neurol Scand. (2005)112:103e107. https://doi.org/10.1111/j.1600-0404.2005.00432.x 
77. Pal A, Fontanilla D, Gopalakrishnan A, Chae YK, Markley JL, Ruoho AE. The sigma-1 receptor 
protects  against  cellular  oxidative  stress  and  activates  antioxidant  response  elements.  Eur  J 
Pharmacol. (2012) 682:12e20. https://doi.org/10.1016/j.ejphar.2012.01.030 
78. Dominique Fontanilla et al. The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous 
Sigma-1 Receptor Regulator. Science; (2009) 323 (5916): 934–937.   
https://doi.org/10.1126/science.1166127 
  79.  Carbonaro, T.  M. &  Gatch, M.  B. Neuropharmacology of  N,N-dimethyltryptamine. Brain Res. 
  Bull. (2016) 126, 74–88. https://doi.org/10.1016/j.brainresbull.2016.04.016 
80. Wallach, J. V. Endogenous hallucinogens as ligands of the trace amine receptors: A possible role 
in sensory perception. Med. Hypotheses (2009) 72, 91–94.  
https://doi.org/10.1016/j.mehy.2008.07.052 
81. Barker, S. A., Monti, J. A. & Christian, S. T. N,N-Dimethyltryptamine: An Endogenous Halluci
 nogen.  in  International  Review  of  Neurobiology  Elsevier  (1981)  vol.  22  83–110. 
https://doi.org/10.1016/S0074-7742(08)60291-3 
82.  Wyatt, R.  J., Saavedra, J. M. & Axelrod, J. A Dimethyltryptamine-Forming  Enzyme in  Human 
Blood. Am. J. Psychiatry (1973) 130, 754–760. https://doi.org/10.1176/ajp.130.7.754 
83. Mandell, A. J. & Morgan, M. Indole(ethyl)amine N-Methyltransferase in Human Brain. Nature. 
New Biol. (1971) 230, 85–87. https://doi.org/10.1038/newbio230085a0 
  84. Mavlyutov, T. A. et al. Development of the sigma-1 receptor in C-terminals of motoneurons and 
  colocalization  with  the  N,N′-dimethyltryptamine  forming  enzyme,  indole-N-methyl  transferase. 
  Neuroscience (2012) 206, 60–68. https://doi.org/10.1016/j.neuroscience.2011.12.040 
85. Thompson, M. A. & Weinshilboum, R. M. Rabbit Lung Indolethylamine N-Methyltransferase. J. 
Biol. Chem. (1998) 273, 34502–34510. https://doi.org/10.1074/jbc.273.51.34502 
  86.  Morgan,  M.  &  Mandell,  A.  J.  Indole(ethyl)amine  N  -Methyltransferase  in  the  Brain.  Science 
  (1969) 165, 492–493. https://doi.org/10.1126/science.165.3892.492 
87.  Nichols,  D.  E.  N,N  -dimethyltryptamine  and  the  pineal  gland:  Separating  fact  from  myth.  J. 
Psychopharmacol. (Oxf.) (2018) 32, 30–36. https://doi.org/10.1177/0269881117736919 
88. Jiménez, J. H. & Bouso, J. C. Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-
year-old debate. J. Psychopharmacol. (Oxf.) (2022) 36, 905–919.   
https://doi.org/10.1177/02698811221104054 
  89. Mavlyutov, T. A. et al. Development of the sigma-1 receptor in C-terminals of motoneurons and 
  colocalization  with  the  N,N′-dimethyltryptamine  forming  enzyme,  indole-N-methyl  transferase. 
  Neuroscience (2012) 206, 60–68. https://doi.org/10.1016/j.neuroscience.2011.12.040 
90. Vitale, A. A. et al. In Vivo Long-Term Kinetics of Radiolabeled N , N -Dimethyltryptamine and 
Tryptamine. J. Nucl. Med. (2011) 52, 970–977. https://doi.org/10.2967/jnumed.110.083246 
  91. Frecska, E., Szabo, A., Winkelman, M. J., Luna, L. E. & McKenna, D. J. A possibly sigma-1 recep
  tor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. J. Neural 
  Transm. (2013) 120, 1295–1303. https://doi.org/10.1007/s00702-013-1024-y 
92.  Cozzi, N.  V. et al.  Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate 
behavior  at  the  serotonin  uptake  transporter  and  the  vesicle  monoamine  transporter.  J.  Neural 
Transm. (2009) 116, 1591–1599. https://doi.org/10.1007/s00702-009-0308-8 

Milena Batalla                                                                                                             Science Reviews - Biology, 2023, 2(2), 1 - 20                                                                                                                                                                          
16 
 
  93. B R Sitaram, L Lockett, R Talomsin, G L Blackman, W R McLeod. In vivo metabolism of 5-me
  thoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat. Biochem Pharmacol; (1987) 
  36 (9):1509-12. https://doi.org/10.1016/0006-2952(87)90118-3 
94. Ryskamp, D. A., Korban, S., Zhemkov, V., Kraskovskaya, N. & Bezprozvanny, I. Neuronal Sigma-
1  Receptors:  Signaling  Functions  and  Protective  Roles  in  Neurodegenerative  Diseases.  Front. 
Neurosci. (2019) 13, 862. https://doi.org/10.3389/fnins.2019.00862 
  95. Kourrich, S., Su, T.-P., Fujimoto, M. & Bonci, A. The sigma-1 receptor: roles in neuronal plasticty 
  and disease. Trends Neurosci. (2012) 35, 762–771. https://doi.org/10.1016/j.tins.2012.09.007 
96.  Ruscher,  K. et  al. The  sigma-1  receptor enhances brain plasticity  and functional recovery after 
experimental stroke. Brain (2011) 134, 732–746. https://doi.org/10.1093/brain/awq367 
97. Szabo, A., Kovacs, A., Frecska, E. & Rajnavolgyi, E. Psychedelic N,N-Dimethyltryptamine and 5-
Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through 
the Sigma-1 Receptor  of Human  Monocyte-Derived  Dendritic Cells.  PLoS ONE (2014)  9, e106533. 
https://doi.org/10.1371/journal.pone.0106533 
98. Osório, F. de L. et al. Antidepressant effects of a single dose of ayahuasca in patients with recur
 rent  depression:  a  preliminary  report.  Rev.  Bras.  Psiquiatr.  (2015)  37,  13–20. 
https://doi.org/10.1590/1516-4446-2014-1496 
99. Uthaug, M. V. et al. A placebo-controlled study of the effects  of ayahuasca, set and setting on 
mental health  of participants in  ayahuasca group  retreats. Psychopharmacology (Berl.) (2021) 238, 
1899–1910. https://doi.org/10.1007/s00213-021-05817-8 
  100. Morales-Garcia, J. A. et al. N,N-dimethyltryptamine compound found in the hallucinogenic tea 
  ayahuasca,  regulates  adult  neurogenesis  in  vitro  and  in  vivo.  Transl.  Psychiatry  (2020)  10,  331. 
  https://doi.org/10.1038/s41398-020-01011-0 
101.  Weil  AT,  Davis W.  Bufo  alvarius:  a  potent  hallucinogen  of animal  origin.  J Ethnopharmacol 
(1994) 41:1–8. https://doi.org/10.1016/0378-8741(94)90051-5 
102.  Fiona  G.  Sleight,  Steven  Jay  Lynn,  Richard  E.  Mattson,  Charlie  W.  McDonald.  A  novel  ego 
dissolution  scale:  A  construct  validation  study.  Consciousness  and  Cognition  (2023)  109,  103474. 
https://doi.org/10.1016/j.concog.2023.103474 
  103. S. F. Cooke and T. V. P. Bliss. Plasticity in the human central nervous system. Brain, (2006) 129, 
  1659–1673. https://doi.org/10.1093/brain/awl082 
104. Ruscher, K. et al. The sigma-1 receptor enhances brain plasticity and functional recovery after 
experimental stroke. Brain (2011) 134, 732–746. https://doi.org/10.1093/brain/awq367 
  105. Tsai, S.-Y. et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free ra
  dical-sensitive  mechanism involving Rac1·GTP  pathway.  Proc. Natl.  Acad. Sci.  (2009)  106, 22468–
  22473. https://doi.org/10.1073/pnas.0909089106 
106. Endris, V. et al. The novel Rho-GTPase activating gene MEGAP / srGAP3 has a putative role in 
severe mental retardation. Proc. Natl. Acad. Sci. (2002) 99, 11754–11759.  
https://doi.org/10.1073/pnas.162241099 
107. Mueller, B. H. et al. Sigma-1 receptor stimulation attenuates calcium influx through activated L-
type Voltage Gated Calcium Channels in purified retinal ganglion cells. Exp. Eye Res. (2013) 107, 21–
31. https://doi.org/10.1016/j.exer.2012.11.002 
108.  Tchedre,  K.  T. &  Yorio,  T.  σ-1  Receptors  Protect  RGC-5  Cells  from Apoptosis  by  Regulating 
Intracellular Calcium, Bax Levels, and Caspase-3 Activation. Investig. Opthalmology Vis. Sci. (2008) 
49, 2577.  https://doi.org/10.1167/iovs.07-1101 

Science Reviews - Biology, 2023, 2(2), 1 - 20                                                                                                             Milena Batalla                      
17 
 
109. Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type 
 experiences having  substantial and sustained personal meaning and spiritual significance. Psycho
 pharmacology  (Berl.)  (2006)  187,  268–83  discussion  284–92.  https://doi.org/10.1007/s00213-006-
0457-5 
110. Shaughnessy DT, McAllister K, Worth L, Haugen AC, Meyer JN, Domann FE, Van Houten B, 
Mostoslavsky R, Bultman SJ, Baccarelli AA, Begley TJ, Sobol RW, Hirschey MD, Ideker T, Santos JH, 
Copeland WC, Tice RR, Balshaw DM, Tyson FL. Mitochondria, energetics, epigenetics, and cellular 
responses to stress. Environ Health Perspect (2014) 122:1271–1278.   
https://doi.org/10.1289/ehp.1408418 
  111. Kourrich, S., Su, T.-P., Fujimoto, M. & Bonci, A. The sigma-1 receptor: roles in neuronal plastici
  ty and disease. Trends Neurosci. (2012) 35, 762–771. https://doi.org/10.1016/j.tins.2012.09.007 
112. Thomas Misgeld and Thomas L. Schwarz. Mitostasis in neurons: Maintaining mitochondria in 
an extended cellular architecture. Neuron. (2017) 96(3): 651–666.   
 https://doi.org/10.1016/j.neuron.2017.09.055 
113. Teresa E. Daniels, Elizabeth M. Olsen and Audrey R. Tyrka. Stress and Psychiatric Disorders: 
The  Role  of  mitochondria.  The  Annual  Review  of  Clinical  Psychology  (2020)  16:165–86. 
https://doi.org/10.1146/annurev-clinpsy-082719-104030 
114.  Bertogliat,  M.  J.,  Morris-Blanco,  K.  C.  &  Vemuganti,  R.  Epigenetic  mechanisms  of 
neurodegenerative  diseases  and  acute  brain  injury.  Neurochem.  Int.  (2020)  133,  104642. 
https://doi.org/10.1016/j.neuint.2019.104642  
  115.  Feinberg,  A.  P.  Epigenetics  at  the  Epicenter  of  Modern  Medicine.  JAMA  (2008)  299,  1345. 
  https://doi.org/10.1001/jama.299.11.1345 
116. Chandra, D. & Singh, K. K. Genetic insights into OXPHOS defect and its role in cancer. Biochim. 
Biophys. Acta BBA - Bioenerg. (2011) 1807, 620–625.  https://doi.org/10.1016/j.bbabio.2010.10.023 
117. Szulwach, K. E. & Jin, P. Integrating DNA methylation dynamics into a framework for under
 standing  epigenetic  codes:  Prospects  &  Overviews.  BioEssays  (2014)  36,  107–117.  
https://doi.org/10.1002/bies.201300090 
118.  Kriaucionis,  S.  &  Heintz,  N.  The  Nuclear  DNA  Base  5-Hydroxymethylcytosine  Is  Present  in 
Purkinje Neurons and the Brain. Science (2009) 324, 929–930.   
https://doi.org/10.1126/science.1169786 
119. Tahiliani, M. et al. Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian 
DNA by MLL Partner TET1. Science (2009) 324, 930–935. https://doi.org/10.1126/science.1170116 
120. Shock, L. S., Thakkar, P. V., Peterson, E. J., Moran, R. G. & Taylor, S. M. DNA methyltransferase 
1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. Proc. Natl. 
Acad. Sci. (2011) 108, 3630–3635. https://doi.org/10.1073/pnas.1012311108 
  121. Barile, M., Brizio, C., Valenti, D., De Virgilio, C. & Passarella, S. The riboflavin/FAD cycle in rat 
  liver  mitochondria:  Riboflavin/FAD  cycle  in  RLM.  Eur.  J.  Biochem.  (2000)  267,  4888–4900. 
  https://doi.org/10.1046/j.1432-1327.2000.01552.x 
122.  Berkich,  D.  A.,  Xu,  Y.,  LaNoue,  K.  F.,  Gruetter,  R.  &  Hutson,  S.  M.  Evaluation  of  brain 
mitochondrial  glutamate  and alpha-ketoglutarate  transport  under  physiologic  conditions.  J. 
Neurosci. Res. (2005) 79, 106–113. https://doi.org/10.1002/jnr.20325 
  123. Gibson, G. E., Starkov, A., Blass, J. P., Ratan, R. R. & Beal, M. F. Cause and consequence: Mito
  chondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavio
  ral abnormalities in age-associated neurodegenerative diseases. Biochim. Biophys. Acta BBA - Mol. 
  Basis Dis. (2010) 1802, 122–134. https://doi.org/10.1016/j.bbadis.2009.08.010 

Milena Batalla                                                                                                             Science Reviews - Biology, 2023, 2(2), 1 - 20                                                                                                                                                                          
18 
 
124. Singh, K. Mitochondria damage checkpoint in apoptosis and genome stability. FEMS Yeast Res. 
(2004) 5, 127–132. https://doi.org/10.1016/j.femsyr.2004.04.008 
125.  Balinang,  J.  The  Regulation  of  Mitochondrial  DNMT1  During  Oxidative  Stress. 
Theses/Dissertations (2012). https://doi.org/10.25772/4ZS0-8P80 
  126. Dostal, V. & Churchill, M. E. A. Cytosine methylation of mitochondrial DNA at CpG sequences 
  impacts transcription factor A DNA binding and transcription. Biochim. Biophys. Acta BBA - Gene 
  Regul. Mech. (2019) 1862, 598–607. https://doi.org/10.1016/j.bbagrm.2019.01.006 
127.  Van  der  Wijst,  M.  G.  P.  &  Rots,  M.  G.  Mitochondrial  epigenetics:  an  overlooked  layer  of 
regulation? Trends Genet. (2015) 31, 353–356. https://doi.org/10.1016/j.tig.2015.03.009 
  128.  Michela  Fagiolini,  Catherine  L  Jensen  and  Frances  A  Champagne.  Epigenetic  influences  on 
  brain  development  and  plasticity.  Current  Opinion  in  Neurobiology  (2009),  19:207–212. 
  https://doi.org/10.1016/j.conb.2009.05.009 
129. Ali Jawaid, Martin Roszkowski, Isabelle M. Mansuy. Transgenerational Epigenetics of Traumatic 
Stress.  Progress  in  Molecular  Biology  and  Translational  Science  (2018)  1-20. 
https://doi.org/10.1016/bs.pmbts.2018.03.003 
130.  Dora  L.  Costaa,  Noelle  Yetterb,  and  Heather  DeSomerb.  Intergenerational  transmission  of 
paternal  trauma  among  US  Civil  War  ex-POWs.  PNAS  (2018)  115,  44,  11215–11220. 
https://doi.org/10.1073/pnas.1803630115 
131.  Natan  P.F.  Kellermann.  Epigenetic  Transmission  of  Holocaust  Trauma:  Can  Nightmares  Be 
Inherited? Isr J Psychiatry Relat Sci (2013) 50, 1. 
  132. Yehuda, R. & Bierer, L. M. The relevance of epigenetics to PTSD: Implications for the DSM-V: 
  Epigenetics  and  PTSD:  Implications  for  the  DSM-V.  J.  Trauma.  Stress  (2009)  22,  427–434. 
  https://doi.org/10.1002/jts.20448 
133. Pérez-Mediavilla, A. & Zamarbide, M. Maternal imprinting, mitochondrial DNA, nuclear DNA 
and  Alzheimer’s  disease.  Explor.  Neuroprotective  Ther.  (2021)  1,  121–126. 
https://doi.org/10.37349/ent.2021.00010 
  134. Bai, Q. & Burton, E. A. Zebrafish models of Tauopathy. Biochim. Biophys. Acta BBA - Mol. Ba
  sis Dis. (2011) 1812, 353–363. https://doi.org/10.1016/j.bbadis.2010.09.004 
135. Das, S. & Rajanikant, G. K. Huntington disease: Can a zebrafish trail leave more than a ripple? 
Neurosci. Biobehav. Rev. (2014) 45, 258–261. https://doi.org/10.1016/j.neubiorev.2014.06.013 
136. Laird, A. S., Mackovski, N., Rinkwitz, S., Becker, T. S. & Giacomotto, J. Tissue-specific models of 
spinal muscular atrophy confirm a critical role of SMN in motor neurons from embryonic to adult 
stages. Hum. Mol. Genet. (2016) 25, 1728–1738. https://doi.org/10.1093/hmg/ddw044 
137. Crouzier, L. et al. Sigma-1 Receptor Is Critical for Mitochondrial Activity and Unfolded Protein 
Response in Larval Zebrafish. Int. J. Mol. Sci. (2021) 22, 11049.   
https://doi.org/10.3390/ijms222011049  
  138. Goguadze, N., Zhuravliova, E., Morin, D., Mikeladze, D. & Maurice, T. Sigma-1 Receptor Ago
  nists  Induce  Oxidative  Stress  in  Mitochondria  and  Enhance  Complex  I  Activity  in  Physiological 
  Condition  but  Protect  Against  Pathological  Oxidative  Stress.  Neurotox.  Res.  (2019)  35,  1–18. 
  https://doi.org/10.1007/s12640-017-9838-2 
139. Batalla, M. Therapeutic uses of all-natural 5-meo-dmt enrichment from glandular secretion of 
Bufo alvarius toad from the Sonoran Desert. Patent application number (2022) US63/415407. 
  140. Yaden, Andrew B. Newberg. The Varieties of Spiritual Experience: 21st Century Research and 
  Perspectives.  Chapter  12,  Mystical  Experiences:  Unity  and  Ego-Dissolution.  (2022)  Pages  224–
  C12.P140. https://doi.org/10.1093/oso/9780190665678.001.0001 

Science Reviews - Biology, 2023, 2(2), 1 - 20                                                                                                             Milena Batalla                      
19 
 
141.  Reckweg,  J.  T.  et  al.  The  clinical  pharmacology  and  potential  therapeutic  applications  of  5‐
methoxy‐N,N‐dimethyltryptamine  (5‐MeO‐DMT).  J.  Neurochem.  (2022)  162,  128–146. 
https://doi.org/10.1111/jnc.15587 
142.  Use  of  Benefit  Enhancement  Strategies  among  5-Methoxy-N,N-Dimethyltryptamine  (5-MeO-
DMT)  Users:  Associations  with  Mystical,  Challenging,  and  Enduring  Effects. 
https://doi.org/10.1080/02791072.2020.1737763 
143. Reckweg, J. et al. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a 
Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. Front. 
Pharmacol. (2021) 12, 760671. https://doi.org/10.3389/fphar.2021.760671 
  144. Moylan, S., Maes, M., Wray, N. R. & Berk, M. The neuroprogressive nature of major depressive 
  disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychia
  try (2013) 18, 595–606. https://doi.org/10.1038/mp.2012.33 
145. Konradi, C. et al. Molecular Evidence for Mitochondrial Dysfunction in Bipolar Disorder. Arch. 
Gen. Psychiatry (2004) 61, 300. https://doi.org/10.1001/archpsyc.61.3.300 
146. Fattal, O., Link, J., Quinn, K., Cohen, B. H. & Franco, K. Psychiatric Comorbidity in 36 Adults 
 with Mitochondrial Cytopathies. CNS Spectr. (2007) 12, 429–438.   
https://doi.org/10.1017/S1092852900015303 
147. Hollis, F. et al. Mitochondrial function in the brain links anxiety with social subordination. Proc. 
Natl. Acad. Sci. (2015) 112, 15486–15491. https://doi.org/10.1073/pnas.1512653112 
148.  Zuccoli,  G.  S.,  Saia-Cereda,  V.  M.,  Nascimento,  J.  M.  &  Martins-de-Souza,  D.  The  Energy 
Metabolism Dysfunction in Psychiatric Disorders Postmortem Brains: Focus on Proteomic Evidence. 
Front. Neurosci. (2017) 11, 493. https://doi.org/10.3389/fnins.2017.00493 
149.  Tsai,  S.-Y.  A.  et  al.  Sigma-1  receptor  mediates  cocaine-induced  transcriptional  regulation  by 
recruiting chromatin-remodeling factors  at the  nuclear envelope.  Proc. Natl.  Acad. Sci. (2015) 112. 
https://doi.org/10.1073/pnas.1518894112 
150.  Sha,  S.  et  al.  Sigma-1  Receptor  Knockout  Impairs  Neurogenesis  in  Dentate  Gyrus  of  Adult 
Hippocampus Via Down-Regulation of NMDA Receptors. CNS Neurosci. Ther. (2013) 19, 705–713. 
https://doi.org/10.1111/cns.12129 
151.  Uthaug, M. V.  et  al. A  single inhalation  of  vapor  from  dried  toad  secretion  containing  5-me
 thoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhan
 cement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopatholo
 gical symptoms. Psychopharmacology (Berl.) (2019) 236, 2653–2666.   
https://doi.org/10.1007/s00213-019-05236-w 
152. Davis,  A. K.,  Barsuglia, J.  P.,  Lancelotta, R.,  Grant,  R. M.  & Renn,  E. The  epidemiology of  5-
methoxy-  N,  N  -dimethyltryptamine  (5-MeO-DMT)  use:  Benefits,  consequences,  patterns  of  use, 
subjective  effects,  and  reasons  for  consumption.  J.  Psychopharmacol.  (Oxf.)  (2018)  32,  779–792. 
https://doi.org/10.1177/0269881118769063 
153.  Chiamulera,  C.  et  al.  Reinforcing  and  locomotor  stimulant  effects  of  cocaine  are  absent  in 
 mGluR5 null mutant mice. Nat. Neurosci. (2001) 4, 873–874.   
https://doi.org/10.1177/0269881118769063 
154.  Bird,  M.  K.,  Kirchhoff,  J.,  Djouma,  E.  &  Lawrence,  A.  J.  Metabotropic  glutamate  5  receptors 
regulate  sensitivity  to  ethanol  in  mice.  Int.  J.  Neuropsychopharmacol.  (2008)  11. 
https://doi.org/10.1017/S1461145708008572 
155.  Barsuglia,  J.  P.  et  al.  A  case  report  SPECT  study  and  theoretical  rationale  for  the  sequential 
administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. in Progress in 
Brain Research (2018) vol. 242, 121–158. https://doi.org/10.1016/bs.pbr.2018.08.002 

Milena Batalla Science Reviews - Biology, 2023, 2(2), 1 - 20

156. Inserra, A. Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1

Receptor-Mediated Epigenetic-Mnemonic Process. Front. Pharmacol. (2018) 9, 330.

https://doi.org/10.3389/fphar.2018.00330

157. Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P. & Amoroso, T. Psychedelic Treatment

for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces

Veterans. Chronic Stress (2020) 4, 247054702093956. https://doi.org/10.1177/2470547020939564

158. Kourrich, S., Su, T.-P., Fujimoto, M. & Bonci, A. The sigma-1 receptor: roles in neuronal plasticity

and disease. Trends Neurosci. (2012) 35, 762–771. https://doi.org/10.1016/j.tins.2012.09.007

159. Ben-Shachar, D. & Karry, R. Neuroanatomical Pattern of Mitochondrial Complex I Pathology

Varies between Schizophrenia, Bipolar Disorder and Major Depression. PLoS ONE (2008) 3, e3676.

https://doi.org/10.1371/journal.pone.0003676

160. Tsai, S.-Y. A., Pokrass, M. J., Klauer, N. R., De Credico, N. E. & Su, T.-P. Sigma-1 receptor

chaperones in neurodegenerative and psychiatric disorders. Expert Opin. Ther. Targets (2014) 1–16.

https://doi.org/10.1517/14728222.2014.972939

The study did not involve humans or animals.

Conflict of Interest statement

The author is inventor on patent application describing therapeutic uses of all-natural 5-MeO-DMT.